EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Add‐On Telitacicept Significantly Improves Outcome of Patients With Refractory Ocular Myasthenia Gravis a Real‐World Case Series

Jing Lin, Yue Li, Mengcui Gui, Bitao Bu, Zhijun Li

Brain and Behavior · 2026

DOI: 10.1002/brb3.71157 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain and Behavior, 2026. Verfasst von Jing Lin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Hauptthemen laut MEDLINE: Myasthenia Gravis, Recombinant Fusion Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Commission of Hubei Province scientific research project, Natural Science Foundation of Hubei Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Refractory ocular myasthenia gravis (MG) represents a significant therapeutic challenge, as conventional immunotherapies often prove ineffective. Telitacicept, a recombinant B‐lymphocyte stimulator receptor‐antibody fusion protein, offers a novel immunomodulatory approach. This retrospective study evaluates its efficacy and safety in patients with MG‐associated refractory ocular symptoms.

Methods

This is a single‐center retrospective cohort study. evaluated patients with refractory ocular symptoms who received telitacicept weekly between August 2024 and January 2025. We evaluated treatment efficacy using Myasthenia Gravis Foundation of America post‐intervention status (MGFA‐PIS), Myasthenia Gravis Impairment Index‐patient‐reported outcome (MGII‐PRO), quantitative MG (QMG), and MG activity of daily living (ADL) scores, as well as the reduction in daily prednisone dosage at baseline and each month following treatment. The safety assessment was also evaluated.

Results

Seven MGFA class 1 patients (5 females, 2 males) were enrolled, with a median onset age of 6 years (interquartile range [IQR] 2–21) and a median disease duration of 98 months (IQR 46–121). MG‐ADL scores showed significant reduction with prolonged follow‐up. 6/7 patients achieved ≥2‐point MG‐ADL improvement by the third follow‐up. 4/6 patients reached minimal symptom expression at the fifth follow‐up. The average ocular MG‐ADL, MGII‐PRO, and QMG scores revealed statistically significant improvements at the third month of follow‐up, sustained through the sixth month. The regimen exhibited excellent tolerability, with no severe adverse events (e.g., hypersensitivity reactions, infections) reported.

Conclusion

Our preliminary findings indicate that telitacicept represents a promising and well‐tolerated adjunct therapy for refractory ocular symptoms in MG, providing significant clinical evidence to support this novel therapeutic approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myasthenia GravisRecombinant Fusion ProteinsHumansFemaleMaleRetrospective StudiesMiddle AgedAdultTreatment OutcomeYoung AdultAgedAdolescentChildPrednisoneDrug Therapy, CombinationPatient Reported Outcome Measures

Stichwörter der Autor:innen

B‐cell activating factorminimal symptom expressionrefractory ocular myasthenia gravistelitacicept

Substanzen

Recombinant Fusion ProteinsTACI receptor-IgG Fc fragment fusion proteinPrednisonetelitacicept

Autor:innen und Institutionen

  • Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

Förderung

  • Health Commission of Hubei Province scientific research project
  • Natural Science Foundation of Hubei Province
  • National Natural Science Foundation of China

Zitieren

APA

Lin, J., Li, Y., Gui, M., Bu, B., & Li, Z. (2026). Add‐On Telitacicept Significantly Improves Outcome of Patients With Refractory Ocular Myasthenia Gravis a Real‐World Case Series. Brain and Behavior. https://doi.org/10.1002/brb3.71157

Vancouver

Lin J, Li Y, Gui M, Bu B, Li Z. Add‐On Telitacicept Significantly Improves Outcome of Patients With Refractory Ocular Myasthenia Gravis a Real‐World Case Series. Brain and Behavior. 2026. doi:10.1002/brb3.71157

BibTeX
@article{Lin2026,
  author = {Lin, Jing and Li, Yue and Gui, Mengcui and Bu, Bitao and Li, Zhijun},
  title = {Add‐On Telitacicept Significantly Improves Outcome of Patients With Refractory Ocular Myasthenia Gravis a Real‐World Case Series},
  journal = {Brain and Behavior},
  year = {2026},
  doi = {10.1002/brb3.71157}
}
Kostenlos starten →